Habiba Atta

Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.

Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.

An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A meta-analysis found teleophthalmology satisfaction comparable to in-person eye care, but showed a gap between recommending it and reusing it.

Gray market peptides often contain far less drug than labeled and may carry toxins like arsenic, warns Catherine Varney, DO.

Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, says Catherine Varney, DO.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

OCT patterns help distinguish MS, NMOSD, and MOGAD after optic neuritis, while timing and protocol shape MRI's diagnostic yield, experts say.

At inSPire2026, experts highlighted gaps in specialty therapy payment, 340B data, clinical trials, and AI-driven care.

No biomarker yet predicts individual response to MG therapies, but preventing exacerbations can help reduce utilization, said Richard Nowak, MD, MS.

As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.

Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.

At NASP's inSPire2026, covered entities and manufacturers debate 340B program reform, contract pharmacies, and the 2027 rebate model.

Switching MS patients to subcutaneous ocrelizumab cut chair time 82.8% and delivered $514,544 in 3-year value, a UVA analysis finds.

A narrative review finds specialty pharmacies lack a patient-reported outcome measure built for their workflow, despite frequent contact with patients with MS.

Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.

Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.

A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.

Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Inebilizumab's twice-yearly CD19 dosing directly targets antibody-producing cells; trial enrollment used disease activity, not treatment failure.

Women with endometriosis have a 46% higher type 2 diabetes risk, highest among premenopausal, non-obese women, study finds.

Even with MINT's mandatory steroid taper, inebilizumab still cut exacerbation and rescue therapy rates versus placebo, said Richard Nowak, MD, MS

The FDA cleared PrecivityAD2, a blood test from C2N Diagnostics that helps diagnose Alzheimer disease in adults as young as 40.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

New Harris Poll data show mental health, access, and postpartum care gaps persist for US mothers, with Black and Hispanic women hit hardest.

The ACCESS program gave underinsured patients free specialty eye care at one center, restoring vision and cutting disability costs, a study found.

Follow-up length varied by subgroup in the MINT trial, but inebilizumab cut exacerbations and rescue therapy use consistently.

Hospital resources, not clinical preference, often decide which MG rescue therapy a patient receives, Richard Nowak, MD, MS, said.